In the context of type 2 diabetes, Sivadas et al. [250] analyzed over 1000 Indian genomes and described a distinctive distribution of CYP3A4 and CYP3A5 variants that may predispose to clinically significant drug–drug and gene–drug interactions involving non-insulin antidiabetic drugs (NIADs). This evidence concerns the gene CYP3A5 and type 2 diabetes mellitus.